| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
GN25 (10 and 20 μM; 24 h) decreases the viability of MEF cells with a K-Ras mutation[1]. In a K-Ras-dependent manner, p53 is activated by GN25 (5 μM; 4 h)[1]. In K-Ras-mutant A549 and HCT116 cell lines, GN25 (1 -10 μM; 1-6 h) activates p53 and p21 in a dose- and time-dependent manner[1]. In p53WT/MT cells, GN25 activates wild-type p53[1]. The masking effect of p53 on CK1/GSK3b-mediated Snail phosphorylation is recovered by GN25 (0.25 μM)[1].
|
|---|---|
| ln Vivo |
In mice, GN25 (10 and 20 mg/kg; i.p. once weekly for 10 weeks) inhibits the growth of tumors and causes tumor regression[1].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: HCT116, A459 and MKN45 cell lines Tested Concentrations: 10 μM Incubation Duration: 24 h Experimental Results: Obviously suppressed the cell viability of HCT116 and A459 cell lines. Cell Proliferation Assay[1] Cell Types: K-Ras-transformed and N-Ras/Myc-transformed MEF cells Tested Concentrations: 10 μM and 20 μM Incubation Duration: 24 h Experimental Results: Inhibited the viability of K-Ras-transformed but not N-Ras/Myc-transformed MEF cells. Western Blot Analysis[1] Cell Types: K-Ras-MEF, N-Ras/Myc-MEF and Nontransformed MEF cells Tested Concentrations: 5 μM Incubation Duration: 4 h Experimental Results: Only induced p53 and p21 in K-Ras-MEF cells. Western Blot Analysis[1] Cell Types: K-Ras-mutated A549, HCT116 cell lines and MKN45 Tested Concentrations: 1, 5, and 10 μM Incubation Duration: 1, 3, and 6 h Experimental Results: Induced p53 and p21 in a dose- and time-dependent manner in A549 and HCT116 cells. |
| Animal Protocol |
Animal/Disease Models: Athymic mice with A549 xenografts[1]
Doses: 10 and 20 mg/kg Route of Administration: intraperitoneal (ip)injection; once a week for 10 weeks Experimental Results: Obviously regressed tumors in mice. demonstrated no significant toxicity in liver, pancreas and kidney. |
| References |
| Molecular Formula |
C15H14O6S
|
|---|---|
| Molecular Weight |
322.33
|
| Exact Mass |
322.051
|
| CAS # |
1227401-27-5
|
| PubChem CID |
46218884
|
| Appearance |
Light yellow to orange solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
608.4±55.0 °C at 760 mmHg
|
| Flash Point |
321.7±31.5 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.622
|
| LogP |
2.19
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
22
|
| Complexity |
500
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
DIIRLGMLDOPLPV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H14O6S/c1-20-9-3-4-10(21-2)14-13(9)8(16)7-11(15(14)19)22-6-5-12(17)18/h3-4,7H,5-6H2,1-2H3,(H,17,18)
|
| Chemical Name |
3-(5,8-dimethoxy-1,4-dioxonaphthalen-2-yl)sulfanylpropanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (310.24 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1024 mL | 15.5121 mL | 31.0241 mL | |
| 5 mM | 0.6205 mL | 3.1024 mL | 6.2048 mL | |
| 10 mM | 0.3102 mL | 1.5512 mL | 3.1024 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
